What I Read This Week...

Salesforce stock drops more than 20% after releasing Q2 earnings, investor sentiment is shifting on generative AI, and a new drug offers the possibility of tooth regeneration in humans

Watch All-In E181 Read our latest deep dive into semiconductors Caught My Eye… Salesforce’s share price dropped more than 20% after releasing its Q2 2024 earnings, despite earnings falling just 0.3% below Wall Street analysts' expectations. What's going on? Two factors appear to be responsible for this decline. First, a slowing economy poses a risk to revenues as customers more carefully evaluate the return on investment of Salesforce’s products before committing to a purchase. Second, analysts are concerned that generative AI could help competitors deliver similar functionalities to…

related reading

• THE 2028 GLOBAL INTELLIGENCE CRISIScitriniresearch.com
• The Fall of the Nerdsnoahpinion.blog
• Generative AI’s Act Two | Sequoia Capitalsequoiacap.com
• The ROI on Generative AItanayj.com
• How Salesforce became Silicon Valley's best late-stage tech investorcnbc.com
• "Death of a Salesforce": Why AI Will Transform the Next Generation of Sales Tech | Andreessen Horowitza16z.com
• AI Market Clarity - by Elad Gil - Elad Blogblog.eladgil.com
• Generative AI's Act o1: The Reasoning Era Begins | Sequoia Capitalsequoiacap.com
• The Golden Age of AI Applicationstomtunguz.com
• THE 2028 GLOBAL INTELLIGENCE CRISISsubstack.com
• The State of Generative AI, 2024 - by Alberto Romerothealgorithmicbridge.com
• Random thoughts while gazing at the misty AI Frontierblog.eladgil.com